Skip to main content

Lung inflammation in Cystic Fibrosis – a novel method paves the way to an improved understanding and treatment

|   News

A team of TLRC researchers at the European Molecular Biology Laboratory (EMBL) and University Hospital Heidelberg (UKHD) have developed a novel tool to measure the activity of two proteins implicated in lung inflammation in cystic fibrosis. The activity of the proteases neutrophil elastase (NE) and cathepsin G (CG) was visualised on extracellular DNA secreted by immune cells (neutrophil extracellular traps - NETs), using the fluorescence-based reporter system FRET. For the first time, this method allowed quantification of DNA-bound NE activity inside the sputum of CF-patients. The results were published in the Journal of the American Chemical Society and might help to advance research into novel diagnostic and therapeutic approaches for cystic fibrosis and other lung diseases involving chronic inflammation.

Most patients with cystic fibrosis (CF) suffer from a persistent inflammation of their lungs, which in the long term leads to permanent structural damage of the airways and consequently a reduction of lung function. The underlying genetic defect that causes CF changes the composition of mucus inside the airways, making it more viscous. This thick mucus blocks the airways and promotes bacterial growth, triggering an immune reaction and resulting in inflammation of the lung.

Neutrophils are cells at the immunity frontline that combat bacterial pathogens on different levels.  Firstly, they ingest and destroy bacterial invaders, secondly, they communicate with the immune system e.g. to sustain the immune response. This communication is mediated by various molecules, two of them are the proteases neutrophil elastase (NE) and cathepsin G (CG). Further, neutrophils have a third, more sophisticated way of dealing with bacterial invaders: they secrete their DNA, to form web-like extracellular structures, or so-called neutrophil extracellular traps (NET). These can trap the bacteria and form a scaffold for molecules like NE and CG, possibly helping to locally fine tune the immune response.

But there are also downsides to high neutrophil activity, which become apparent when the inflammation persists – as it does in the lungs of CF patients. One problem is, that the DNA that neutrophils secrete blocks the airways of CF patients even further and disrupts the flow of air. Therefore, DNAses, which degrade DNA, are already used in CF therapy to free the airways and to promote breathing. A second problem of high neutrophil activity is, that the neutrophil proteases NE and CG are known stimulators of inflammation. If their activity is too high, they might contribute to the body’s immune system to attack its own cells, resulting in permanent lung damage. The presence of NE in the lung secretions of CF patients precedes the appearance of bronchiectasis and correlates with lung function deterioration and exacerbations. Therefore, NE and CG might become valuable biomarkers in the future, e.g. to estimate disease severity and to predict exacerbations, or deterioration in lung function.

So far, it has not been possible to study the activity of NE and CG when bound to NETs easily. Methods used in the past were time consuming and involved the sectioning of lung tissue. Therefore, the TLRC team developed a novel fluorescence-based FRET-reporter system to measure the proteolytic activity of CG and NE bound to DNA. Using this tool, they detected elevated levels of NET-bound NE activity in the sputum of CF patients. This is a first promising step towards application of the method in clinical studies. Such studies could shed light on the role of NETs and NET-bound NE and CG in lung inflammation in CF. It could be investigated whether NET-bound NE and CG activity in the sputum of CF-patients could serve as a biomarker, predicting the need for anti-inflammatory therapy. Also, the new technique could help to understand the role of NETs, NE and CG in other lung diseases that are characterised by chronic inflammation such as asthma and COPD.

/ TLRC - Doreen Penso Dolfin

Further information:

Protease FRET Reporters Targeting Neutrophil Extracellular Traps. Guerra M, Halls VS, Schatterny J, Hagner M, Mall MA, Schultz C. J Am Chem Soc. 2020 Nov 13. doi: 10.1021/jacs.0c08130. Online ahead of print. PMID: 33186023